[开放获取]   长波紫外线1皮肤科临床应用专家共识（2022）

doi:10.35541/cjd.20220423

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (11): 956-961.doi: 10.35541/cjd.20220423

[开放获取] 长波紫外线1皮肤科临床应用专家共识（2022）

中国研究型医院学会皮肤科学专业委员会中国医师协会皮肤科医师分会

中国研究型医院学会皮肤科学专业委员会中国医师协会皮肤科医师分会

收稿日期:2022-06-13 修回日期:2022-08-21 发布日期:2022-11-03
通讯作者: 顾恒；陈崑 E-mail:guheng@aliyun.com; Kunchen181@aliyun.com

Clinical application of ultraviolet A1 in dermatology: an expert consensus statement （2022）

^{Dermatology Professional Committee of Chinese Research Hospital Society; China Dermatologist Association}

Dermatology Professional Committee of Chinese Research Hospital Society; China Dermatologist Association

Received:2022-06-13 Revised:2022-08-21 Published:2022-11-03
Contact: Gu Heng; Chen Kun E-mail:guheng@aliyun.com; Kunchen181@aliyun.com

摘要/Abstract

摘要： 【摘要】长波紫外线1（UVA1）在皮肤疾病治疗中已有较广泛的应用，与传统的UVA加补骨脂素（PUVA）以及中波紫外线光疗法相比，UVA1不仅穿透较深，而且无PUVA相关光毒反应等不良反应，为局限性硬皮病、特应性皮炎及蕈样肉芽肿等提供了新的治疗方法。为保障UVA1光疗的有效性及安全性，相关领域专家基于国内外临床研究数据及临床经验，在充分讨论后拟定本共识，从UVA1光谱特性及作用机制、适应证及禁忌证、治疗方案、常见不良反应与处理等方面阐述，为皮肤科临床医师提供指导意见。

关键词: 紫外线疗法, 皮肤疾病, 治疗应用, 硬皮病, 局部性, 皮炎, 特应性, 蕈样肉芽肿, UVA1, 专家共识

Abstract: 【Abstract】 Ultraviolet A1 （UVA1） has been proven to be useful in the treatment of a lot of dermatoses. UVA1 not only has stronger penetrativity than ultraviolet B （UVB） does, but also has no adverse effects such as phototoxic reactions compared with psoralen plus ultraviolet A radiation （PUVA）, which provides a new therapy for localized scleroderma, atopic dermatitis, mycosis fungoides, etc. In order to ensure the efficacy and safety of UVA1 phototherapy, relevant experts developed this consensus after full discussions based on clinical research data and experience. The consensus elaborates on the spectral characteristics, mechanisms of action, indications and contraindications, treatment regimens of, as well as adverse reactions induced by UVA1 phototherapy, providing guidance for dermatologists in clinical practice.

Key words: Ultraviolet therapy, Skin diseases, Therapeutic uses, Scleroderma, localized, Dermatitis, atopic, Mycosis fungoides, UVA1, Expert consensus

中国研究型医院学会皮肤科学专业委员会中国医师协会皮肤科医师分会 . [开放获取] 长波紫外线1皮肤科临床应用专家共识（2022）[J]. 中华皮肤科杂志, 2022,55(11):956-961. doi:10.35541/cjd.20220423

Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Clinical application of ultraviolet A1 in dermatology: an expert consensus statement （2022）[J]. Chinese Journal of Dermatology, 2022, 55(11): 956-961.doi:10.35541/cjd.20220423

参考文献 61

［1］	Krutmann J, Czech W, Diepgen T, et al. High⁃dose UVA1 therapy in the treatment of patients with atopic dermatitis［J］. J Am Acad Dermatol, 1992,26（2 Pt 1）:225⁃230. doi: 10.1016/0190⁃9622（92）70031⁃a.
［2］	Masuda H, Morita A. Ultraviolet A1 phototherapy utilizing ultraviolet light⁃emitting diodes and a short wavelength cutoff filter［J］. J Dermatol Sci, 2021,101（2）:138⁃140. doi: 10.1016/j.jdermsci.2020.11.004.
［3］	Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies［J］. Clin Dermatol, 2013,31（4）:438⁃454. doi: 10.1016/j.clindermatol.2013.01.011.
［4］	Shunko A. Inada. Development of an ultraviolet A1 light emitting diode⁃based device for phototherapy［J］. Open Dermatol J, 2012, 6:13⁃24. doi: 10.2174/1874372201206010013.
［5］	Wan P, Edwards C, Zheng J, et al. Validation of a novel high⁃intensity LED light source for skin phototesting at 365 nm［J］. Photodermatol Photoimmunol Photomed, 2012,28（2）:80⁃83. doi: 10.1111/j.1600⁃0781.2011.00641.x.
［6］	Gambichler T, Skrygan M, Tomi NS, et al. Differential expression of decorin in localized scleroderma following ultraviolet⁃A1 irradiation［J］. J Am Acad Dermatol, 2007,56（6）:956⁃959. doi: 10.1016/j.jaad.2006.10.961.
［7］	Stege H, Berneburg M, Humke S, et al. High⁃dose UVA1 radiation therapy for localized scleroderma［J］. J Am Acad Dermatol, 1997,36（6 Pt 1）:938⁃944. doi: 10.1016/s0190⁃9622（97）80277⁃0.
［8］	鞠梅, 张青松, 张小华, 等. 不同剂量UVA1辐射硬皮病鼠模型的研究［J］. 中华皮肤科杂志, 2009,42（1）:8⁃11. doi: 10. 3760/cma.j.issn.0412⁃4030.2009.01.004.
［9］	鞠梅, 陈崑, 常宝珠, 等. 不同剂量UVA1辐射对硬皮病鼠模型皮肤匀浆CD34和M30的影响［J］. 中华皮肤科杂志, 2011,44（3）:178⁃181. doi: 10.3760/cma.j.issn.0412⁃4030.2011.03.009.
［10］	Skov L, Hansen H, Allen M, et al. Contrasting effects of ultraviolet A1 and ultraviolet B exposure on the induction of tumour necrosis factor⁃alpha in human skin［J］. Br J Dermatol, 1998,138（2）:216⁃220. doi: 10.1046/j.1365⁃2133.1998.02063.x.
［11］	Trompezinski S, Pernet I, Mayoux C, et al. Transforming growth factor⁃beta1 and ultraviolet A1 radiation increase production of vascular endothelial growth factor but not endothelin⁃1 in human dermal fibroblasts［J］. Br J Dermatol, 2000,143（3）:539⁃545. doi: 10.1111/j.1365⁃2133.2000.03707.x.
［12］	Godar DE. UVA1 radiation triggers two different final apoptotic pathways［J］. J Invest Dermatol, 1999,112（1）:3⁃12. doi: 10.1046/ j.1523⁃1747.1999.00474.x.
［13］	Walker D, Jacobe H. Phototherapy in the age of biologics［J］. Semin Cutan Med Surg, 2011,30（4）:190⁃198. doi: 10.1016/j.sder.2011.08.004.
［14］	Zandi S, Kalia S, Lui H. UVA1 phototherapy: a concise and practical review［J］. Skin Therapy Lett, 2012,17（1）:1⁃4.
［15］	Barros NM, Sbroglio LL, Buffara MO, et al. Phototherapy［J］. An Bras Dermatol, 2021,96（4）:397⁃407. doi: 10.1016/j.abd.2021. 03.001.
［16］	Tuchinda C, Kerr HA, Taylor CR, et al. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States［J］. Photodermatol Photoimmunol Photomed, 2006,22（5）:247⁃253. doi: 10.1111/j.1600⁃0781.2006.00245.x.
［17］	Zhou J, Yi X, Li Y, et al. Efficacy assessment of UVA1 and narrowband UVB for treatment of scalp psoriasis［J］. Lasers Med Sci, 2018,33（9）:1979⁃1982. doi: 10.1007/s10103⁃018⁃2564⁃z.
［18］	Totonchy MB, Chiu MW. UV⁃based therapy［J］. Dermatol Clin, 2014,32（3）:399⁃413, ix⁃x. doi: 10.1016/j.det.2014.03.003.
［19］	Andres C, Kollmar A, Mempel M, et al. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study［J］. Br J Dermatol, 2010,162（2）:445⁃447. doi: 10.1111/j.1365⁃2133.2009.09438.x.
［20］	Sator PG, Radakovic S, Schulmeister K, et al. Medium⁃dose is more effective than low⁃dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20⁃MHz ultrasound assessment［J］. J Am Acad Dermatol, 2009,60（5）:786⁃791. doi: 10.1016/j.jaad.2008.12.013.
［21］	Kreuter A, Hyun J, Stücker M, et al. A randomized controlled study of low⁃dose UVA1, medium⁃dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma［J］. J Am Acad Dermatol, 2006,54（3）:440⁃447. doi: 10.1016/j.jaad.2005.11.1063.
［22］	Abeck D, Schmidt T, Fesq H, et al. Long⁃term efficacy of medium⁃dose UVA1 phototherapy in atopic dermatitis［J］. J Am Acad Dermatol, 2000,42（2 Pt 1）:254⁃257. doi: 10.1016/S0190⁃9622（00）90134⁃8.
［23］	Pacifico A, Iacovelli P, Damiani G, et al. ′High dose′ vs. ′medium dose′ UVA1 phototherapy in italian patients with severe atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2019,33（4）:718⁃724. doi: 10.1111/jdv.15362.
［24］	Trovato E, Pellegrino M, Filippi F, et al. Clinical and histological evaluation in patients with mycosis fungoides treated with UVA1［J］. G Ital Dermatol Venereol, 2020,155（3）:306⁃311. doi: 10.23736/S0392⁃0488.18.05867⁃4.
［25］	Su LN, Ren J, Cheng SM, et al. UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study［J］. Lasers Med Sci, 2017,32（8）:1819⁃1823. doi: 10.1007/s10103⁃017⁃2280⁃0.
［26］	El⁃Mofty M, Mostafa W, Youssef R, et al. Ultraviolet A in vitiligo［J］. Photodermatol Photoimmunol Photomed, 2006,22（4）:214⁃216. doi: 10.1111/j.1600⁃0781.2006.00229.x.
［27］	Lotti T, Tchernev G, Wollina U, et al. Successful treatment with UVA 1 laser of non ⁃ responder vitiligo patients［J］. Open Access Maced J Med Sci, 2018,6（1）:43⁃45. doi: 10.3889/oamjms.2018.047.
［28］	Petering H, Breuer C, Herbst R, et al. Comparison of localized high⁃dose UVA1 irradiation versus topical cream psoralen⁃UVA for treatment of chronic vesicular dyshidrotic eczema［J］. J Am Acad Dermatol, 2004,50（1）:68⁃72. doi: 10.1016/s0190⁃9622（03）00782⁃5.
［29］	Polderman MC, Govaert JC, le Cessie S, et al. A double⁃blind placebo⁃controlled trial of UVA⁃1 in the treatment of dyshidrotic eczema［J］. Clin Exp Dermatol, 2003,28（6）:584⁃587. doi: 10. 1046/j.1365⁃2230.2003.01378.x.
［30］	Gambichler T, Hyun J, Sommer A, et al. A randomised controlled trial on photo（chemo）therapy of subacute prurigo［J］. Clin Exp Dermatol, 2006,31（3）:348⁃353. doi: 10.1111/j.1365⁃2230.2006.02081.x.
［31］	Gobello T, Mazzanti C, Sordi D, et al. Medium⁃ versus high⁃dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study［J］. J Am Acad Dermatol, 2003,49（4）:679⁃684. doi: 10.1067/s0190⁃9622（03）01483⁃x.
［32］	Lim SH, Kim SM, Oh BH, et al. Low⁃dose ultraviolet A1 phototherapy for treating pityriasis rosea［J］. Ann Dermatol, 2009,21（3）:230⁃236. doi: 10.5021/ad.2009.21.3.230.
［33］	Gambichler T, Schmitz L. Ultraviolet A1 phototherapy for fibrosing conditions［J］. Front Med （Lausanne）, 2018,5:237. doi: 10.3389/fmed.2018.00237.
［34］	Herz⁃Ruelas ME, Gomez⁃Flores M, Miranda⁃Maldonado I, et al. Escalating dosimetry of UVA⁃1 in the treatment of alopecia areata［J］. Int J Dermatol, 2017,56（6）:653⁃659. doi: 10.1111/ijd.13572.
［35］	Herz⁃Ruelas ME, Welsh O, Gomez⁃Flores M, et al. Ultraviolet A⁃1 phototherapy as an alternative for resistant alopecia areata［J］. Int J Dermatol, 2015,54（10）:e445⁃e447. doi: 10.1111/ijd.13054.
［36］	Kreuter A, Breuckmann F, Uhle A, et al. Low⁃dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis［J］. J Am Acad Dermatol, 2004,50（5）:740⁃747. doi: 10.1016/j.jaad. 2003.08.026.
［37］	Polat M, Kaya H, Şahin A. A new approach in the treatment of keloids: UVA⁃1 laser［J］. Photomed Laser Surg, 2016,34（3）:130⁃133. doi: 10.1089/pho.2015.4046.
［38］	Eberlein⁃König B, Vogel M, Katzer K, et al. Successful UVA1 phototherapy in a patient with scleredema adultorum［J］. J Eur Acad Dermatol Venereol, 2005,19（2）:203⁃204. doi: 10.1111/j. 1468⁃3083.2005.00935.x.
［39］	Mertens JS, Seyger M, Thurlings RM, et al. Morphea and eosinophilic fasciitis: an update［J］. Am J Clin Dermatol, 2017,18（4）:491⁃512. doi: 10.1007/s40257⁃017⁃0269⁃x.
［40］	Schaller M, Romiti R, Wollenberg A, et al. Improvement of cutaneous manifestations in POEMS syndrome after UVA1 phototherapy［J］. J Am Acad Dermatol, 2001,45（6）:969⁃970. doi: 10.1067/mjd.2001.117248.
［41］	Joshi TP, Duvic M. Granuloma annulare: an updated review of epidemiology, pathogenesis, and treatment options［J］. Am J Clin Dermatol, 2022,23（1）:37⁃50. doi: 10.1007/s40257⁃021⁃00636⁃1.
［42］	Feily A, Yaghoobi R, Nilforoushzadeh MA. Treatment modalities of palmoplantar lichen planus: a brief review［J］. Postepy Dermatol Alergol, 2016,33（6）:411⁃415. doi: 10.5114/ada.2016. 63879.
［43］	Grundmann⁃Kollmann M, Behrens S, Gruss C, et al. Chronic sclerodermic graft⁃versus⁃host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy［J］. J Am Acad Dermatol, 2000,42（1 Pt 1）:134⁃136. doi: 10. 1016/s0190⁃9622（00）90023⁃9.
［44］	Knobler R, Moinzadeh P, Hunzelmann N, et al. European Dermatology Forum S1⁃guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes［J］. J Eur Acad Dermatol Venereol, 2017,31（9）:1401⁃1424. doi: 10.1111/jdv. 14458.
［45］	黄茂芳, 田歆, 罗育武, 等. 中剂量UVA1光疗对11例斑块状硬皮病的临床疗效观察［J］. 皮肤性病诊疗学杂志, 2015,（2）:109⁃111. doi: 10.3969/j.issn.1674⁃8468.2015.02.007.
［46］	Gambichler T, Othlinghaus N, Tomi NS, et al. Medium⁃dose ultraviolet （UV） A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study［J］. Br J Dermatol, 2009,160（3）:652⁃658. doi: 10.1111/j.1365⁃2133.2008.08984.x.
［47］	Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part I［J］. J Eur Acad Dermatol Venereol, 2018,32（5）:657⁃682. doi: 10.1111/jdv.14891.
［48］	Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium⁃dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis［J］. J Am Acad Dermatol, 2009,60（1）:77⁃84. doi: 10.1016/j.jaad.2008.08.048.
［49］	Malinowska K, Woźniacka A, Bogaczewicz J. The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis［J］. Postepy Dermatol Alergol, 2020,37（6）:962⁃967. doi: 10.5114/ada.2019. 88465.
［50］	Park JB, Jang JY, Kwon DI, et al. The effectiveness of high⁃dose ultraviolet A⁃1 phototherapy for acute exacerbation of atopic dermatitis in Asians［J］. Photodermatol Photoimmunol Photomed, 2020,36（4）:263⁃270. doi: 10.1111/phpp.12546.
［51］	Zane C, Leali C, Airò P, et al. "High⁃dose" UVA1 therapy of widespread plaque⁃type, nodular, and erythrodermic mycosis fungoides［J］. J Am Acad Dermatol, 2001,44（4）:629⁃633. doi: 10.1067/mjd.2001.110896.
［52］	Polańska A, Osmola⁃Mańkowska A, Olek⁃Hrab K, et al. High⁃frequency ultrasonography in objective evaluation of the efficacy of PUVA and UVA 1 phototherapy in mycosis fungoides［J］. Arch Dermatol Res, 2017,309（8）:645⁃651. doi: 10.1007/s00403⁃017⁃1767⁃7.
［53］	Adışen E, Tektaş V, Erduran F, et al. Ultraviolet A1 phototherapy in the treatment of early mycosis fungoides［J］. Dermatology, 2017,233（2⁃3）:192⁃198. doi: 10.1159/000458149.
［54］	Zerbinati N, Portale S, Palmieri B, et al. A preliminary study to assess the efficacy of a new UVA1 laser for treatment of psoriasis［J］. Photomed Laser Surg, 2012,30（10）:610⁃614. doi: 10.1089/pho.2012.3281.
［55］	Silpa⁃Archa N, Pattanaprichakul P, Charoenpipatsin N, et al. The efficacy of UVA1 phototherapy in psoriasis: clinical and histological aspects［J］. Photodermatol Photoimmunol Photomed, 2020,36（1）:21⁃28. doi: 10.1111/phpp.12498.
［56］	高芸璐, 丁杨峰, 易雪梅. UVA1和窄波UVB光疗治疗斑块型银屑病的随机对照研究［J］. 中国中西医结合皮肤性病学杂志, 2018,17（2）:161⁃164. doi: 10.3969/j.issn.1672⁃0709.2018.02. 022.
［57］	El⁃Zawahry BM, Elmasry MF, Ragab A. The role of long⁃wavelength ultraviolet A1 （UVA1） in acral vitiligo［J］. J Cosmet Dermatol, 2019,18（4）:1155⁃1160. doi: 10.1111/jocd.12808.
［58］	El⁃Zawahry BM, Bassiouny DA, Sobhi RM, et al. A comparative study on efficacy of UVA1 vs. narrow⁃band UVB phototherapy in the treatment of vitiligo［J］. Photodermatol Photoimmunol Photomed, 2012,28（2）:84⁃90. doi: 10.1111/j.1600⁃0781.2011. 00643.x.
［59］	Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases［J］. Photodermatol Photoimmunol Photomed, 2008,24（1）:19⁃23. doi: 10.1111/j.1600⁃0781.2008.00328.x.
［60］	Welsh O. Phototherapy for alopecia areata［J］. Clin Dermatol, 2016,34（5）:628⁃632. doi: 10.1016/j.clindermatol.2016.05.014.
［61］	Hofbauer G. Phototherapy and carcinogenesis［J］. Hautarzt, 2013,64（5）:349⁃353. doi: 10.1007/s00105⁃013⁃2587⁃0.

[1]	晋亮刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(8): 735-739.
[2]	徐哲. 对遗传性皮肤病的一些思考[J]. 中华皮肤科杂志, 2022, 55(8): 651-652.
[3]	魏瑾臧东杰曾三武蒋靖伦文辉. Dowling-Degos病1家系KRT5基因新突变分析[J]. 中华皮肤科杂志, 2022, 55(8): 703-705.
[4]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[5]	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470.
[6]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[7]	黄馨陈筱昀李亚萍梁兴堃张桂英周英湛意罗帅寒天廖洁月肖嵘龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493.
[8]	徐西光卢彬孙建方. 表现为特应性皮炎样皮损的X连锁无丙种球蛋白血症1例[J]. 中华皮肤科杂志, 2022, 55(6): 536-537.
[9]	陆晓云张曾云鸥肖风丽. 上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用[J]. 中华皮肤科杂志, 2022, 55(6): 548-551.
[10]	孙晓丽李邻峰. 肥大细胞在变应性接触性皮炎发病中的作用进展[J]. 中华皮肤科杂志, 2022, 55(5): 449-451.
[11]	闪莹左亚刚. 自身免疫性疱病与银屑病的相关性[J]. 中华皮肤科杂志, 2022, 55(5): 452-455.
[12]	申晨陶娟. 特应性皮炎长期控制的评估演变与达标治疗[J]. 中华皮肤科杂志, 2022, 55(5): 442-445.
[13]	李丹琪楼雨晨陶娟. 大剂量静脉注射免疫球蛋白在重症皮肤病治疗中的应用进展[J]. 中华皮肤科杂志, 2022, 55(5): 455-459.
[14]	王傲姚煦. 特应性皮炎瘙痒机制的研究进展[J]. 中华皮肤科杂志, 2022, 55(4): 357-361.
[15]	余愫郁天泽李巍. 自主神经在特应性皮炎免疫失调中的作用[J]. 中华皮肤科杂志, 2022, 55(4): 362-365.

[开放获取] 长波紫外线1皮肤科临床应用专家共识（2022）

Clinical application of ultraviolet A1 in dermatology: an expert consensus statement （2022）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 61

相关文章 15

Metrics

本文评价

推荐阅读 10